Supportive Information:

Marlene Ågerstrand, Mattheus Brenig, Martin Führ, Julian Schenten. 2017. Refining tools to bridge the gap between academia and chemicals regulation: Perspectives for a WikiREACH.

Questionnaire incl. frequency of replies. Where applicable, the authors will provide respondent comments on request.

Q1 Which sector are you associated with? Select all that apply. (N=30)
- ❑ Academia (4)
- ❑ Regulatory agency (13)
- ❑ Industry (6)
- ❑ Consultancy firm (1)
- ❑ Other, please specify (6)*

Q2 How did you find out about WikiPharma? Select all that apply. (N=30)
- ❑ Colleagues (9)
- ❑ MistraPharma (13)
- ❑ Research article (1)
- ❑ Conference presentation (2)
- ❑ Other please specify (5)*

Q3 How do you rate the awareness level of WikiPharma in your professional peer group? Choose one of the following answers. (N=28)
- ○ Low (9)
- ○ Moderately low (6)
- ○ Moderately high (12)
- ○ High (1)

Q4 For what purpose have you used WikiPharma? Select all that apply. (N=25)
- ❑ As a resource when performing own laboratory research (6)
- ❑ As a resource when performing risk or hazard assessments (21)
- ❑ To increase the reach of own research by entering data (0)
- ❑ To increase the reach of own research by proposing entry of own research to database operator (1)
- ❑ Other, please specify (4)*

Q5 How do you rate the scientific credibility of the WikiPharma approach (i.e., researchers add their own data to the database)? Choose one of the following answers. (N=26)
- ○ Low (2)
- ○ Moderately low (5)
- ○ Moderately high (17)
- ○ High (2)

Q6 Have you or your organization produced peer-reviewed ecotoxicity studies about pharmaceuticals? Choose one of the following answers. (N=26)

- ❍ Yes (13)
- ❍ No (11)
- ❍ Don't know (2)

Q7 If yes, have you added data derived from these studies to WikiPharma? Choose one of the following answers. (N=13)

- ❍ Yes (1)
- ❍ No (8)
- ❍ Don't know (4)

Q8 If no, why haven't you added data derived from these studies to WikiPharma? Select all that apply. (N=10)

- ❑ Unaware of that option at WikiPharma (3)
- ❑ Too labor intense to create an account in WikiPharma and then manually add data to each section (1)
- ❑ No direct benefit within the academic system (no reach, no citations, no social networking, etc.) (0)
- ❑ Unaware of the regulatory use of WikiPharma (i.e. the possible regulatory impact of adding my studies) (1)
- ❑ The studies were already added by the administrator (1)
- ❑ Other, please specify (4)*

Q9 Do you see any benefits for researchers in adding data to WikiPharma? Choose one of the following answers. (N=25)

- ❍ Yes, please comment (20)*
- ❍ No, please comment (0)*
- ❍ Don't know (5)

Q10 What motivates/would motivate you to add data to WikiPharma? Select all that apply. (N=24)

- ❑ Knowing it may have regulatory impact (14)
- ❑ Additional scores by web tools such as ResearchGate (e.g. in form of an "interaction"-score) (2)
- ❑ Request from funding agencies to communicate results outside of academia (9)
- ❑ Knowing that it may increase citations (5)
- ❑ A hyperlink that connects the provided data with publicly available literature databases hosting the article the data is retrieved from (8)
- ❑ Nothing (4)
- ❑ Other, please specify (3)*

Q11 In your perspective, how important is it to increase the awareness among risk assessors about peer-reviewed ecotoxicity studies (GLP/non-GLP) on pharmaceuticals that can be used in regulatory assessments? Choose one of the following answers. (N=25)
- ◯ Very important (21)
- ◯ Moderately important (3)
- ◯ Slightly important (1)
- ◯ Not important (0)

Q12 How often do you visit WikiPharma? Choose one of the following answers. (N=26)
- ◯ Weekly (2)
- ◯ Monthly (2)
- ◯ Less often (18)
- ◯ Never (4)

Q13 Have information gathered from WikiPharma been useful for you or your organization's work (e.g. as a literature screening tool or for regulatory decisions)? Choose one of the following answers. (N=25)
- ◯ Yes, please comment (17)*
- ◯ No, please comment (3)*
- ◯ Don't know (5)

Q14 Do you have any suggestions on how WikiPharma could be improved, for example in terms of contributions from academia and regulatory impact? (N=7)*

Q15 Do you see a need to develop databases (or similar tools) for other groups of chemicals (e.g. pesticides, industrial chemicals [in the EU: covered by REACH], cosmetic substances) to increase the use of peer-reviewed studies in regulatory assessments? Choose one of the following answers. (N=22)
- ◯ Yes, please comment (12)*
- ◯ No, please comment (2)*
- ◯ Don't know (8)

Q16 Do you have ideas on how such tools should be developed and designed, which key stakeholders to involve, and other comments that could help in the process? (N=5)*

*The authors will provide respondent comments on request.